Levodopa-induced dyskinesias and their management

Francesca Del Sorbo, Alberto Albanese

Research output: Contribution to journalArticle

Abstract

This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease. These are a common clinical problem occurring in up to 90 % of patients and more frequently affect those with early-onset. Dyskinesias have a negative impact on quality of life and are an important cause of disability. Their precise etiology is still poorly understood, although it is recognized that dopaminergic pre-synaptic and post-synaptic mechanisms are involved together with extra-dopaminergic factors. The phenomenology of dyskinesias encompasses a variable mixture of two prevalent features: dystonia and chorea. We have studied their time course following a single acute levodopa challenge and have found that dystonia occurs throughout the duration of the on period, whereas choreiform movements occur only at the peak of therapeutic dopaminergic motor responses. This allows a schematic relationship to be drawn between a short duration motor response and the occurrence of dystonia and chorea. There is currently no satisfactory treatment for dyskinesias. Managing the therapeutic window does not provide an adequate solution due to the appearance of a dyskinesia threshold dose that narrows the therapeutic margin. High frequency stimulation of the subthalamic nucleus probably has some specific anti-dyskinetic action, but is limited by the small number of patients who are candidates for this treatment. Research efforts are currently focused on the development of specific anti-dyskinetic medications. Their availability will certainly change the current clinical practice and will widen again the therapeutic window of dopaminergic medications that has now become too narrow.

Original languageEnglish
Pages (from-to)32-41
Number of pages10
JournalJournal of Neurology
Volume255
Issue numberSUPPL. 4
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Dyskinesias
Levodopa
Chorea
Dystonia
Therapeutics
Subthalamic Nucleus
Parkinson Disease
Epidemiology
Quality of Life
Research

Keywords

  • Dopamine agonists
  • Dyskinesias
  • Levodopa
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Levodopa-induced dyskinesias and their management. / Del Sorbo, Francesca; Albanese, Alberto.

In: Journal of Neurology, Vol. 255, No. SUPPL. 4, 08.2008, p. 32-41.

Research output: Contribution to journalArticle

Del Sorbo, Francesca ; Albanese, Alberto. / Levodopa-induced dyskinesias and their management. In: Journal of Neurology. 2008 ; Vol. 255, No. SUPPL. 4. pp. 32-41.
@article{f57f3648f9e249d88c3eff6d32bb38b8,
title = "Levodopa-induced dyskinesias and their management",
abstract = "This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease. These are a common clinical problem occurring in up to 90 {\%} of patients and more frequently affect those with early-onset. Dyskinesias have a negative impact on quality of life and are an important cause of disability. Their precise etiology is still poorly understood, although it is recognized that dopaminergic pre-synaptic and post-synaptic mechanisms are involved together with extra-dopaminergic factors. The phenomenology of dyskinesias encompasses a variable mixture of two prevalent features: dystonia and chorea. We have studied their time course following a single acute levodopa challenge and have found that dystonia occurs throughout the duration of the on period, whereas choreiform movements occur only at the peak of therapeutic dopaminergic motor responses. This allows a schematic relationship to be drawn between a short duration motor response and the occurrence of dystonia and chorea. There is currently no satisfactory treatment for dyskinesias. Managing the therapeutic window does not provide an adequate solution due to the appearance of a dyskinesia threshold dose that narrows the therapeutic margin. High frequency stimulation of the subthalamic nucleus probably has some specific anti-dyskinetic action, but is limited by the small number of patients who are candidates for this treatment. Research efforts are currently focused on the development of specific anti-dyskinetic medications. Their availability will certainly change the current clinical practice and will widen again the therapeutic window of dopaminergic medications that has now become too narrow.",
keywords = "Dopamine agonists, Dyskinesias, Levodopa, Parkinson's disease",
author = "{Del Sorbo}, Francesca and Alberto Albanese",
year = "2008",
month = "8",
doi = "10.1007/s00415-008-4006-5",
language = "English",
volume = "255",
pages = "32--41",
journal = "Journal of Neurology",
issn = "0340-5354",
publisher = "Dr. Dietrich Steinkopff Verlag GmbH and Co. KG",
number = "SUPPL. 4",

}

TY - JOUR

T1 - Levodopa-induced dyskinesias and their management

AU - Del Sorbo, Francesca

AU - Albanese, Alberto

PY - 2008/8

Y1 - 2008/8

N2 - This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease. These are a common clinical problem occurring in up to 90 % of patients and more frequently affect those with early-onset. Dyskinesias have a negative impact on quality of life and are an important cause of disability. Their precise etiology is still poorly understood, although it is recognized that dopaminergic pre-synaptic and post-synaptic mechanisms are involved together with extra-dopaminergic factors. The phenomenology of dyskinesias encompasses a variable mixture of two prevalent features: dystonia and chorea. We have studied their time course following a single acute levodopa challenge and have found that dystonia occurs throughout the duration of the on period, whereas choreiform movements occur only at the peak of therapeutic dopaminergic motor responses. This allows a schematic relationship to be drawn between a short duration motor response and the occurrence of dystonia and chorea. There is currently no satisfactory treatment for dyskinesias. Managing the therapeutic window does not provide an adequate solution due to the appearance of a dyskinesia threshold dose that narrows the therapeutic margin. High frequency stimulation of the subthalamic nucleus probably has some specific anti-dyskinetic action, but is limited by the small number of patients who are candidates for this treatment. Research efforts are currently focused on the development of specific anti-dyskinetic medications. Their availability will certainly change the current clinical practice and will widen again the therapeutic window of dopaminergic medications that has now become too narrow.

AB - This paper reviews the epidemiology, pathophysiology, clinical features and rationale for managing dyskinesias associated with Parkinson's disease. These are a common clinical problem occurring in up to 90 % of patients and more frequently affect those with early-onset. Dyskinesias have a negative impact on quality of life and are an important cause of disability. Their precise etiology is still poorly understood, although it is recognized that dopaminergic pre-synaptic and post-synaptic mechanisms are involved together with extra-dopaminergic factors. The phenomenology of dyskinesias encompasses a variable mixture of two prevalent features: dystonia and chorea. We have studied their time course following a single acute levodopa challenge and have found that dystonia occurs throughout the duration of the on period, whereas choreiform movements occur only at the peak of therapeutic dopaminergic motor responses. This allows a schematic relationship to be drawn between a short duration motor response and the occurrence of dystonia and chorea. There is currently no satisfactory treatment for dyskinesias. Managing the therapeutic window does not provide an adequate solution due to the appearance of a dyskinesia threshold dose that narrows the therapeutic margin. High frequency stimulation of the subthalamic nucleus probably has some specific anti-dyskinetic action, but is limited by the small number of patients who are candidates for this treatment. Research efforts are currently focused on the development of specific anti-dyskinetic medications. Their availability will certainly change the current clinical practice and will widen again the therapeutic window of dopaminergic medications that has now become too narrow.

KW - Dopamine agonists

KW - Dyskinesias

KW - Levodopa

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=52949152728&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949152728&partnerID=8YFLogxK

U2 - 10.1007/s00415-008-4006-5

DO - 10.1007/s00415-008-4006-5

M3 - Article

C2 - 18821084

AN - SCOPUS:52949152728

VL - 255

SP - 32

EP - 41

JO - Journal of Neurology

JF - Journal of Neurology

SN - 0340-5354

IS - SUPPL. 4

ER -